Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16351007 | 1.00 | XIAP (0.44) | XIAPGRB2CAPN1CTSBPREP | |
| SCHEMBL16330333 | 1.00 | XIAP (0.44) | XIAPGRB2CAPN1CTSBPREP | |
| SCHEMBL16351062 | 0.96 | XIAP (0.47) | XIAPGRB2PREPDPP4DPP7 | |
| SCHEMBL16339217 | 0.96 | XIAP (0.47) | XIAPGRB2PREPDPP4DPP7 | |
| SCHEMBL16330317 | 0.96 | XIAP (0.47) | XIAPGRB2PREPDPP4DPP7 | |
| SCHEMBL29530598 | 0.87 | XIAP (0.53) | XIAPCAPN1CTSBPREPDPP4 | |
| SCHEMBL29655765 | 0.86 | DPP4 (0.52) | XIAPGRB2PREPDPP4DPP7 | |
| SCHEMBL10749197 | 0.85 | XIAP (0.49) | XIAPPREPDPP4DPP7ELANE | |
| SCHEMBL10749206 | 0.85 | XIAP (0.49) | XIAPPREPDPP4DPP7ELANE | |
| SCHEMBL29630574 | 0.84 | CAPN1 (0.49) | XIAPGRB2CAPN1CTSBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO SUISSE S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | XIAP 2140/4885GRB2 756/4885CAPN1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.